Health Trials

First-Line

3

Review clinical trials related to First-Line. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Dec 24, 2024Locations: 1
Eligibility criteria

Age ≥18, male or female; [+8]

Untreated active CNS metastasis or leptomeningeal metastasis. [+11]

Read more
Status: Not yet recruiting

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

This study is designed to explore the efficacy and safety of anlotinib combined with benmelstobart and AG (nab-paclitaxel and gemcitabine) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in metastatic pancreatic cancer.

Participants needed: 104
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: RenJi HospitalUpdated: Oct 1, 2024Locations: 1
Eligibility criteria

18-75 years old (including 18 and 75 years old); [+7]

Previously received treatment with vascular endothelial growth factor receptor (... [+25]

Read more
Status: Recruiting

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.

Participants needed: 52
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Aug 1, 2023Locations: 1
Eligibility criteria

Histologically confirmed initially unresectable MSS/pMMR-type RAS-mutant metasta... [+9]

Previously received bevacizumab or anti-CTLA4, anti-PD-1/PD-L1 therapeutic antib... [+22]

Read more